CRISPR-Cas9, a new chance for somatic gene therapy

被引:6
|
作者
Jordan, Bertrand [1 ,2 ]
机构
[1] Aix Marseille Univ, Hop Adultes Timone, Espace Eth Mediterraneen, EFS,CNRS,UMR ADES 7268, F-13385 Marseille 05, France
[2] CoReBio PACA, F-13288 Marseille 09, France
来源
M S-MEDECINE SCIENCES | 2015年 / 31卷 / 11期
关键词
D O I
10.1051/medsci/20153111018
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Targeted modification of genes ("gene editing") is made much easier by the recently developed CRISPR-Cas9 system. This has raised alarm about possible uses of this technology for germline modification of the human genome; however this technology has less controversial applications, notably for somatic gene therapy with already some striking demonstrations in animal systems. Because of its precision and relative ease of use, CRISPR can be expected to drive a revolution in gene therapy and to turn it into a more mainstream approach.
引用
收藏
页码:1035 / 1038
页数:4
相关论文
共 50 条
  • [1] CRISPR-Cas9: a new and promising player in gene therapy
    Lu Xiao-Jie
    Xue Hui-Ying
    Ke Zun-Ping
    Chen Jin-Lian
    Ji Li-Juan
    JOURNAL OF MEDICAL GENETICS, 2015, 52 (05) : 289 - 296
  • [2] In vivo gene therapy potentials of CRISPR-Cas9
    Xue, H-Y
    Zhang, X.
    Wang, Y.
    Xiaojie, L.
    Dai, W-J
    Xu, Y.
    GENE THERAPY, 2016, 23 (07) : 557 - 559
  • [4] In vivo gene therapy potentials of CRISPR-Cas9
    H-Y Xue
    X Zhang
    Y Wang
    L Xiaojie
    W-J Dai
    Y Xu
    Gene Therapy, 2016, 23 : 557 - 559
  • [5] Unraveling the potential of CRISPR-Cas9 for gene therapy
    Barrangou, Rodolphe
    May, Andrew P.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (03) : 311 - 314
  • [6] CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
    Mbakam, Cedric Happi
    Lamothe, Gabriel
    Tremblay, Guillaume
    Tremblay, Jacques P.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 931 - 941
  • [7] CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
    Cedric Happi Mbakam
    Gabriel Lamothe
    Guillaume Tremblay
    Jacques P. Tremblay
    Neurotherapeutics, 2022, 19 : 931 - 941
  • [9] In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9
    He, Zhi-Yao
    Zhang, Ya-Guang
    Yang, Yu-Han
    Ma, Cui-Cui
    Wang, Ping
    Du, Wei
    Li, Ling
    Xiang, Rong
    Song, Xiang-Rong
    Zhao, Xia
    Yao, Shao-Hua
    Wei, Yu-Quan
    HUMAN GENE THERAPY, 2018, 29 (02) : 223 - 233
  • [10] Controlling CRISPR-Cas9 Gene Editing
    Dowdy, Steven F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (03): : 289 - 290